Fast and accurate diagnosis and the immediate isolation of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are regarded as the most effective measures to restrain the coronavirus disease 2019 (COVID-19) pandemic. Here, we present a high-throughput, multi-index nucleic acid isothermal amplification analyzer (RTisochip™-W) employing a centrifugal microfluidic chip to detect 19 common respiratory viruses, including SARS-CoV-2, from 16 samples in a single run within 90 min. The limits of detection of all the viruses analyzed by the RTisochip™-W system were equal to or less than 50 copies·μL−1, which is comparable to those of conventional reverse transcription polymerase chain reaction. We also demonstrate that the RTisochip™-W system possesses the advantages of good repeatability, strong robustness, and high specificity. Finally, we analyzed 201 cases of preclinical samples, 14 cases of COVID-19-positive samples, 25 cases of clinically diagnosed samples, and 614 cases of clinical samples from patients or suspected patients with respiratory tract infections using the RTisochip™-W system. The test results matched the referenced results well and reflected the epidemic characteristics of the respiratory infectious diseases. The coincidence rate of the RTisochip™-W with the referenced kits was 98.15% for the detection of SARS-CoV-2. Based on these extensive trials, we believe that the RTisochip™-W system provides a powerful platform for fighting the COVID-19 pandemic.

中文翻译：

---

用于快速检测SARS-CoV-2等19种常见呼吸道病毒的高通量、多指标等温扩增平台

快速准确诊断和立即隔离感染严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的患者被认为是抑制 2019 冠状病毒病 (COVID-19) 大流行的最有效措施。在这里，我们展示了一种高通量、多指标核酸等温扩增分析仪 (RTisochip™-W)，它使用离心微流控芯片在单次运行中检测 16 个样本中的 19 种常见呼吸道病毒，包括 SARS-CoV-2 90 分钟 RTisochip™-W系统分析的所有病毒的检出限均等于或小于50 copies·μL−1，与常规逆转录聚合酶链反应的检出限相当。我们还证明了 RTisochip™-W 系统具有重复性好、鲁棒性强、和高度特异性。最后，我们使用 RTisochip™-W 系统分析了来自呼吸道感染患者或疑似患者的 201 例临床前样本、14 例 COVID-19 阳性样本、25 例临床诊断样本和 614 例临床样本。检测结果与参考结果吻合较好，反映了呼吸道传染病的流行特点。RTisochip™-W 与参考试剂盒检测 SARS-CoV-2 的符合率为 98.15%。基于这些广泛的试验，我们相信 RTisochip™-W 系统为抗击 COVID-19 大流行提供了一个强大的平台。以及 614 例使用 RTisochip™-W 系统的呼吸道感染患者或疑似患者的临床样本。检测结果与参考结果吻合较好，反映了呼吸道传染病的流行特点。RTisochip™-W 与参考试剂盒检测 SARS-CoV-2 的符合率为 98.15%。基于这些广泛的试验，我们相信 RTisochip™-W 系统为抗击 COVID-19 大流行提供了一个强大的平台。以及 614 例使用 RTisochip™-W 系统的呼吸道感染患者或疑似患者的临床样本。检测结果与参考结果吻合较好，反映了呼吸道传染病的流行特点。RTisochip™-W 与参考试剂盒检测 SARS-CoV-2 的符合率为 98.15%。基于这些广泛的试验，我们相信 RTisochip™-W 系统为抗击 COVID-19 大流行提供了一个强大的平台。